title: A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetes.
abstract: The TNF-alpha super-family of cytokines comprises structurally related proteins that play pivotal roles in regulating cell death, immune response and inflammation. A new member of the family namely Tumor necrosis factor alpha-Related Apoptosis-Inducing Ligand (TRAIL) is involved not only in apoptosis and immune regulation, but also it has a provocative role in vascular biology as reported recently. In this report we provide evidence that this new function of TRAIL may have a significance in the pathogenesis of diabetes and in particular in the vascular alterations that occur late during the natural history of the illness. Noteworthy, depending on the type of diabetes and on the disease stage, TRAIL can have a dual role, either as immune modulator as well as a regulatory molecule of the vascular wall fitness.
authors.affiliation: Department of Health and Motor Sciences, University of Cassino, Cassino FR, Italy. m.vaccarezza@unicas.it
authors.forename: Mauro
authors.initials: M
authors.lastname: Vaccarezza
authors.forename: Giorgio
authors.initials: G
authors.lastname: Delbello
authors.forename: Giorgio
authors.initials: G
authors.lastname: Zauli
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D050197:Atherosclerosis / Q000209:etiology / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000276:immunology; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000503:physiopathology; D051766:Early Growth Response Protein 1 / Q000502:physiology; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D004730:Endothelium, Vascular / Q000166:cytology; D005786:Gene Expression Regulation; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D008954:Models, Biological; D018448:Models, Immunological; D016328:NF-kappa B / Q000502:physiology; D053244:Osteoprotegerin / Q000502:physiology; D051381:Rats; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000502:physiology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000172:deficiency / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D017540:Tunica Media / Q000378:metabolism; D014471:Umbilical Veins
chemical_list: D051766:Early Growth Response Protein 1; D016328:NF-kappa B; D053244:Osteoprotegerin; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; C506030:TNFRSF11B protein, human; C505653:TNFSF10 protein, human; C506032:Tnfrsf11b protein, rat; C505654:Tnfsf10 protein, mouse; D014409:Tumor Necrosis Factor-alpha